Impaired primary immune response in type-1 diabetes. Functional impairment at the level of APCs and T-cells

Cellular Immunology

Volumn 221, Issue 1, 2003, Pages 15-26

  Spatz, Martin ^a   Eibl, Nicole ^b   Hink, Sandra ^b   Wolf, Hermann M ^c   Fischer, Gottfried F ^d   Mayr, Wolfgang R ^d   Schernthaner, Guntram ^b   Eibl, Martha M ^c  

^a Biomedizinische Forschungsgesellschaft mbH   (Austria)

^b KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^c Immunologische Tagesklinik   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Dendritic cells; Diabetes mellitus; Monocytes; T lymphocyte subsets; Type 1

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DQ ANTIGEN; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; KEYHOLE LIMPET HEMOCYANIN; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CELL FUNCTION; CELL STIMULATION; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MONOCYTE; MONONUCLEAR CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ISOLATION; T LYMPHOCYTE;

EID: 0038030599     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-8749(03)00043-1     Document Type: Article

References (55)

1. Eibl N., Spatz M., Fischer G.F., Mayr W.R., Samstag A., Wolf H.M., Schernthaner G., Eibl M.M. Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study. Clin. Immunol. 103:2002;249-259.
2. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15:1998;539-553.
3. Delovitch T.L., Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity. 7:1997;727-738.
4. + islet-specific T cell clone. Science. 249:1990;1433-1436.
5. Wicker L.S., Leiter E.H., Todd J.A., Renjilian R.J., Peterson E., Fischer P.A., Podolin P.L., Zijlstra M., Jaenisch R., Peterson L.B. β2-microglobulin-deficient NOD mice do not develop insulitis or diabetes. Diabetes. 43:1994;500-504.
6. Kägi D., Ho A., Odermatt B., Zakarian A., Ohashi P.S., Mak T.W. TNF receptor 1-dependent β cell toxicity as an effector pathway in autoimmune diabetes. J. Immunol. 162:1999;4598-4605.
7. Tisch R., Yang X.D., Singer S.M., Liblau R.S., Fugger L., Mcdevitt H.O. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature. 366:1993;72-75.
8. Daniel D., Gill R.G., Schloot N., Wegmann D. Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur. J. Immunol. 25:1995;1056-1062.
9. S. Chaillat-Zucman, I. Djilali-Saiah, J. Timsit, in: Genetic Diversity of HLA, Functional and Medical Implication, Proceedings of the Twelfth International Histocompatibility Workshop and Conference, EDK, Paris, 1997.
10. Barnett A.H., Eff C., Leslie R.D., Pyke D.A. Diabetes in identical twins. A study of 200 pairs. Diabetologia. 20:1981;87-93.
11. Takahashi K., Honeyman M.C., Harrison L.C. Impaired yield, phenotype, and function of monocyte-derived dendritic cells in humans at risk for insulin-dependent diabetes. J. Immunol. 161:1998;2629-2635.
12. Ettinger R.A., Liu A.W., Nepom G.T., Kwok W.W. β57-Asp plays an essential role in the unique SDS stability of HLA-DQA1*0102/DQB 1*0602. αβ protein dimer, the class II MHC allele associated with protection from insulin-dependent diabetes mellitus J. Immunol. 165:2000;3232-3238.
13. De Maria R., Todaro M., Stassi G., Di Blasi F., Giordano M., Galluzzo A., Giordano C. Defective T cell receptor/CD3 complex signaling in human type I diabetes. Eur. J. Immunol. 24:1994;999-1002.
14. Nervi S., Atlan-Gepner C., Fossat C., Vialettes B. Constitutive impaired TCR/CD3-mediated activation of T cells in IDDM patients co-exist with normal co-stimulation pathways. J. Autoimmunol. 13:1999;247-255.
15. Nervi S., Atlan-Gepner C., Kahn-Perles B., Lecine P., Vialettes B., Imbert J., Naquet P. Specific deficiency of p561ck expression in T lymphocytes from type 1 diabetic patients. J. Immunol. 165:2000;5874-5883.
16. Terasaki P., McClelland J., Park M., McCurdy B. Manual of Tissue Typing Techniques. 1974;TIBI, NIAID, NTH, Bethesda.
17. Flo R.W., Naess A., Lund-Johansen F., Maehle B.O., Sjursen H., Lehmann V., Solberg C.O. Negative selection of human monocytes using magnetic particles covered by anti-lymphocyte antibodies. J. Immunol. Methods. 137:1991;89-94.
18. Spatz M., Wolf H.M., Thon V., Gampfer J.M., Eibl M.M. Immune response to the herpes simplex type 1 regulatory proteins ICP8 and VP16 in infected persons. J. Med. Virol. 62:2000;29-36.
19. Bender A., Sapp M., Schuler G., Steinman R.M., Bhardwaj N. Improved methods for the generation of dendritc cells from nonproliferating progenitors in human blood. J. Immunol. Methods. 196:1996;121-135.
20. Jonuleit H., Kuhn U., Muller G., Steinbrink K., Paragnik L., Schmitt E., Knop J., Enk A.H. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27:1997;3135-3142.
21. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor α J. Exp. Med. 179:1994;1109-1118.
22. Alleva D.G., Pavlovich R.P., Grant C., Kaser S.B., Seller D.I. Aberrant macrophage cytokine production is a conserved feature among autoimmune-prone mouse strains: elevated interleukin (IL)-12 and an imbalance in tumor necrosis factor-α and IL-10 define a unique cytokine profile in macrophages from young nonobese diabetic mice. Diabetes. 49:2000;1106-1115.
23. Hogquist K.A., Unanue E.R., Chaplin D.D. Release of IL-1 from mononuclear phagocytes. J. Immunol. 147:1991;2181-2186.
24. Dornmair K., Rothenhausler B., McConnell H.M. Structural intermediates in the reactions of antigenic peptides with MHC molecules. Cold Spring Harb. Symp. Quant. Biol. 54(Pt. 1):1989;409-416.
25. Germain R.N., Hendrix L.R. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding. Nature. 353:1991;134-139.
26. Nelson C.A., Petzold S.J., Unanue E.R. Identification of two distinct properties of class II major histocompatibility complex-associated peptides. Proc. Natl. Acad. Sci. USA. 90:1993;1227-1231.
27. Stern L.J., Wiley D.C. The human class II MHC protein HLA-DR1 assembles as empty. αβ heterodimers in the absence of antigenic peptide Cell. 68:1992;465-477.
28. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
29. Lane P. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86. Ann. N. Y. Acad. Sci. 815:1997;392-400.
30. Chen W., Jin W., Wahl S.M. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor β (TGF-β) production by murine CD4(+) T cells. J. Exp. Med. 188:1998;1849-1857.
31. Balasa B., Van Gunst K., Sarvetnick N. The microbial product lipopolysaccharide confers diabetogenic potential on the T cell repertoire of BDC2.5/NOD mice: implications for the etiology of autoimmune diabetes. Clin. Immunol. 95:2000;93-98.
32. Erlich H.A. HLA class II polymorphism and genetic susceptibility to insulin-dependent diabetes mellitus. Curr. Top. Microbiol. Immunol. 164:1990;41-55.
33. Todd J.A., Bell J.I., Mcdevitt H.O. HLA-DQ β gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature. 329:1987;599-604.
34. Reizis B., Altmann D.M., Cohen I.R. Biochemical characterization of the human diabetes-associated HLA-DQ8 allelic product: similarity to the major histocompatibility complex class II I-A(g)7 protein of non-obese diabetic mice. Eur. J. Immunol. 27:1997;2478-2483.
35. McDouall R.M., Yacoub M., Rose M.L. Isolation, culture, and characterisation of MHC class II-positive microvascular endothelial cells from the human heart. Microvasc. Res. 51:1996;137-152.
36. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 69:1992;11-25.
37. Lanzavecchia A., Lezzi G., Viola A. From TCR engagement to T cell activation: a kinetic view of T cell behavior. Cell. 96:1999;1-4.
38. Lenschow D.J., Walunas T.L., Bluestone J.A. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:1996;233-258.
39. Thompson C.B., Allison J.P. The emerging role of CTLA-4 as an immune attenuator. Immunity. 7:1997;445-450.
40. Kristiansen O.P., Larsen Z.M., Pociot F. CTLA-4 in autoimmune diseases - a general susceptibility gene to autoimmunity? Genes Immun. 1:2000;170-184.
41. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., Thompson C.B., Griesser H., Mak T.W. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science. 270:1995;985-988.
42. Nistico L., Buzzetti R., Pritchard L.E., van der Auwera B., Giovannini C., Bosi E., Larrad M.T., Rios M.S., Chow C.C., Cockram C.S., Jacobs K., Mijovic C., Bain S.C., Barnett A.H., Vandewalle C.L., Schuit F., Gorus F.K., Tosi R., Pozzilli P., Todd J.A. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes, Belgian Diabetes Registry. Hum. Mol. Genet. 5:1996;1075-1080.
43. Nakamura K., Kitani A., Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor β J. Exp. Med. 194:2001;629-644.
44. Bach J.F., Chatenoud L. Tolerance to islet autoantigens in type 1 diabetes. Annu. Rev. Immunol. 19:1901;131-161.
45. Xiao B.G., Zhang G.X., Ma C.G., Link H. Transforming growth factor-β 1 (TGF-β1)-mediated inhibition of glial cell proliferation and down-regulation of intercellular adhesion molecule-1 (ICAM-1) are interrupted by interferon-γ (IFN-γ). Clin. Exp. Immunol. 103:1996;475-481.
46. de Vries J.E. Immunosuppressive and anti-inflammatory properties of interleukin-10. Ann. Med. 27:1995;537-541.
47. Lee M.S., Mueller R., Wicker L.S., Peterson L.B., Sarvetnick N. IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity. J. Exp. Med. 183:1996;2663-2668.
48. Medzhitov R., Janeway C.J. Innate immune recognition: mechanisms and pathways. Immunol. Rev. 173:2000;89-97.
49. Kishimoto T. Interleukin-6 and its receptor in autoimmunity. J. Autoimmun. 5(Suppl. A):1992;123-132.
50. Jahromi M.M., Millward B.A., Demaine A.G. A polymorphism in the promoter region of the gene for interleukin-6 is associated with susceptibility to type 1 diabetes mellitus. J. Interferon. Cytokine Res. 20:2000;885-888.
51. Targher G., Zenari L., Bertolini L., Muggeo M., Zoppini G. Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications. Diabetes Care. 24:2001;956-957.
52. Ettinger R.A., Liu A.W., Nepom G.T., Kwok W.W. Exceptional stability of the HLA-DQA1*0102/DQB1*0602. αβ protein dimer, the class II MHC molecule associated with protection from insulin-dependent diabetes mellitus J. Immunol. 161:1998;6439-6445.
53. Nelson A., Petzold S.J., Unanue E.R. Peptides determine the lifespan of MHC class II molecules in the antigen-presenting cell. Nature. 371:1994;250-252.
54. Schreuder G.M., Hurley C.K., Marsh S.G., Lau M., Maiers M., Kollman C., Noreen H. The HLA dictionary 1999: a summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens. Tissue Antigens. 54:1999;409-437.
55. Bodmer J.G., Marsh S.G., Albert E.D., Bodmer W.F., Bontrop R.E., Dupont B., Erlich H.A., Hansen J.A., Mach B., Mayr W.R., Parham P., Petersdorf E.W., Sasazuki T., Schreuder G.M., Strominger J.L., Svejgaard A., Terasaki P.I. Nomenclature for factors of the HLA system, 1998. Tissue Antigens. 53:1999;407-446.